| Dr Craig G Flinders, MD | |
|
2841 Juniper Dr, Lewiston, ID 83501-4719 | |
| (208) 743-9712 | |
| (208) 298-0212 |
| Full Name | Dr Craig G Flinders |
|---|---|
| Gender | Male |
| Speciality | Pain Medicine - Interventional Pain Medicine |
| Location | 2841 Juniper Dr, Lewiston, Idaho |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1760403893 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0014X | Pain Medicine - Interventional Pain Medicine | M-6560 (Idaho) | Primary |
| Entity Name | Tri-state Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598814352 PECOS PAC ID: 4082502422 Enrollment ID: O20040911000031 |
News Archive
A cutting-edge digital tool that will make it cheaper, safer and faster for pharmaceutical companies to predict protein stability - a vital step in the development of new medicines - is being rolled out by scientists from the UK's University of Bath through their spin-out company, BLOC Labs.
A new study has found that tamoxifen, a well-known breast cancer drug, can counteract some pathologic features in a mouse model of Duchenne muscular dystrophy (DMD). At present, no treatment is known to produce long-term improvement of the symptoms in boys with DMD, a debilitating muscular disorder that is characterized by progressive muscle wasting, respiratory and cardiac impairments, paralysis, and premature death.
Arab states must develop a plan to increase food security and create more jobs in order to meet Millennium Development Goal (MDG) targets by 2015, according to a report published Sunday by the United Nations Development Programme (UNDP), Reuters reports.
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Craig G Flinders, MD 2841 Juniper Dr, Lewiston, ID 83501-4719 Ph: (208) 743-9712 | Dr Craig G Flinders, MD 2841 Juniper Dr, Lewiston, ID 83501-4719 Ph: (208) 743-9712 |
News Archive
A cutting-edge digital tool that will make it cheaper, safer and faster for pharmaceutical companies to predict protein stability - a vital step in the development of new medicines - is being rolled out by scientists from the UK's University of Bath through their spin-out company, BLOC Labs.
A new study has found that tamoxifen, a well-known breast cancer drug, can counteract some pathologic features in a mouse model of Duchenne muscular dystrophy (DMD). At present, no treatment is known to produce long-term improvement of the symptoms in boys with DMD, a debilitating muscular disorder that is characterized by progressive muscle wasting, respiratory and cardiac impairments, paralysis, and premature death.
Arab states must develop a plan to increase food security and create more jobs in order to meet Millennium Development Goal (MDG) targets by 2015, according to a report published Sunday by the United Nations Development Programme (UNDP), Reuters reports.
Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
› Verified 8 days ago
Lyndal E Stoutin, M.D. Pain Medicine Medicare: Medicare Enrolled Practice Location: 2841 Juniper Dr, Lewiston, ID 83501 Phone: 208-743-9712 Fax: 208-298-0212 |